Royalty Pharma PLC
STU : RPD€51.98+2.56%Oct 16 close
Financials
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
USD · reported units. Click a value to inspect its source.
| Reported line item | Apr 1, 2026 to Jun 30, 2026 (current) | Jan 1, 2026 to Jun 30, 2026 | Apr 1, 2025 to Jun 30, 2025 | Jan 1, 2025 to Jun 30, 2025 |
|---|---|---|---|---|
| IncomeStatementAbstract | ||||
| StatementTable | ||||
| ProductOrServiceAxis | ||||
| ProductsAndServicesDomain | ||||
| FinancialRoyaltyAssetsMember | ||||
| RoyaltyIncomeOtherMember | ||||
| StatementLineItems | ||||
| Revenues | ||||
| OperatingExpensesAbstract | ||||
| ProvisionForOtherCreditLosses | ||||
| ProvisionForCreditLossesOnUnfundedCommitments | ||||
| ResearchAndDevelopmentExpense | ||||
| GeneralAndAdministrativeExpense | ||||
| AssetImpairmentCharges | ||||
| CostsAndExpenses | ||||
| OperatingIncomeLoss | ||||
| OtherIncomeAndExpensesAbstract | ||||
| IncomeLossFromEquityMethodInvestments | ||||
| InterestExpenseNonoperating | ||||
| EquitySecuritiesFvNiUnrealizedGainLoss | ||||
| DebtSecuritiesAvailableForSaleUnrealizedGainLoss | ||||
| InterestIncomeOther | ||||
| OtherNonoperatingIncomeExpense | ||||
| NonoperatingIncomeExpense | ||||
| IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | ||||
| IncomeTaxExpenseBenefit | ||||
| ProfitLoss | ||||
| NetIncomeLossAttributableToNoncontrollingInterest | ||||
| NetIncomeLoss | ||||
| EarningsPerShareBasicAbstract | ||||
| EarningsPerShareBasicUSD / share | ||||
| EarningsPerShareDilutedUSD / share | ||||
| WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract | ||||
| WeightedAverageNumberOfSharesOutstandingBasicShares | ||||
| WeightedAverageNumberOfDilutedSharesOutstandingShares |
24 line items · 4 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.